These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1033 related items for PubMed ID: 23786573

  • 1. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ.
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P, Sirohi B, Seibel NL, Hsu JW, Azie N, Wu C, Ruhnke M.
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF, Liew D, Slavin MA, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
    Colombo AL, Ngai AL, Bourque M, Bradshaw SK, Strohmaier KM, Taylor AF, Lupinacci RJ, Kartsonis NA.
    Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT.
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT, Lee TY, Chen YC, Charbonneau C.
    BMC Infect Dis; 2017 Jul 10; 17(1):481. PubMed ID: 28693479
    [Abstract] [Full Text] [Related]

  • 10. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC, Lee CW, Shih HJ, Huang SH, Chiou MJ, See LC.
    J Microbiol Immunol Infect; 2014 Jun 10; 47(3):245-53. PubMed ID: 24246191
    [Abstract] [Full Text] [Related]

  • 11. Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
    Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR, Pappas PG.
    Antimicrob Agents Chemother; 2024 May 02; 68(5):e0158423. PubMed ID: 38526046
    [Abstract] [Full Text] [Related]

  • 12. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll AH, Arrieta A, Micafungin Invasive Candidiasis Study Group.
    Pediatr Infect Dis J; 2008 Sep 02; 27(9):820-6. PubMed ID: 18679151
    [Abstract] [Full Text] [Related]

  • 13. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ, Hille D, Sable CA, Kartsonis NA.
    J Infect; 2005 Jun 02; 50(5):443-9. PubMed ID: 15907554
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Echinocandin use in the neonatal intensive care unit.
    Caudle KE, Inger AG, Butler DR, Rogers PD.
    Ann Pharmacother; 2012 Jan 02; 46(1):108-16. PubMed ID: 22190252
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
    Chen Q, Lin MH, Chen ML, Liu ZY, Chai D, Wang R.
    Chin Med J (Engl); 2012 Jan 02; 125(2):345-51. PubMed ID: 22340571
    [Abstract] [Full Text] [Related]

  • 17. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working Group.
    Lancet; 2007 May 05; 369(9572):1519-1527. PubMed ID: 17482982
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H, Xu YC, Hsueh PR.
    Future Microbiol; 2016 Oct 05; 11():1461-1477. PubMed ID: 27750452
    [Abstract] [Full Text] [Related]

  • 19. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF, Liew D, Slavin MA, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.
    Intern Med J; 2013 Jun 05; 43(6):668-77. PubMed ID: 23461421
    [Abstract] [Full Text] [Related]

  • 20. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
    Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM.
    Clin Infect Dis; 2009 Jun 15; 48(12):1695-703. PubMed ID: 19441981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.